BackRegeneron Pharmaceuticals Overview

Regeneron Pharmaceuticals Long Term Debt

Track Regeneron Pharmaceuticals's long-term debt ($2K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1986.00
100.00% YoYΔ $-2.71B vs prior year quarter

Peer average

Loading

Regeneron Pharmaceuticals Long Term Debt History

Loading

Regeneron Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Regeneron Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Regeneron Pharmaceuticals (REGN) FAQ

As of the most recent data (June 2026), REGN shows a long-term debt of $2K. That compares with $2.7B in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, REGN's long-term debt is now $2K (was $2.7B) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Regeneron Pharmaceuticals is outperforming or lagging.

Tracking REGN's long-term debt over time shows whether Regeneron Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $2K That compares with $2.7B in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Regeneron Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $2K) with ownership activity and broader fundamentals.

Regeneron Pharmaceuticals's long-term debt is $2K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.